title: Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin.
authors.forename: Lionel
authors.initials: L
authors.lastname: Fontao
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Laffitte
authors.forename: Anais
authors.initials: A
authors.lastname: Briot
authors.forename: Gürkan
authors.initials: G
authors.lastname: Kaya
authors.forename: Pascale
authors.initials: P
authors.lastname: Roux-Lombard
authors.forename: Sylvie
authors.initials: S
authors.lastname: Fraitag
authors.forename: Alain A
authors.initials: AA
authors.lastname: Hovnanian
authors.forename: Jean-Hilaire
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000069285:Infliximab; D056770:Netherton Syndrome / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000094632:Thymic Stromal Lymphopoietin
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D003879:Dermatologic Agents; D000069285:Infliximab; D000094632:Thymic Stromal Lymphopoietin